SCHEMBL3016786

SCHEMBL3016786

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
USP2 O75604 2/20 0.46
RECQL P46063 2/20 0.46
HSD17B10 Q99714 1/20 0.46
POLB P06746 4/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 2/20 0.44
LMNA P02545 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 1/20 0.40
TP53 P04637 2/20 0.40
HTT P42858 1/20 0.39
F2RL3 Q96RI0 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
TSHR P16473 2/20 0.39
ACLY P53396 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012512 0.94 USP2 (0.51) MAPTUSP2RECQLHSD17B10POLB
SCHEMBL3010012 0.93 TP53 (0.46) MAPTUSP2RECQLHSD17B10POLB
SCHEMBL3003853 0.92 MAPT (0.48) MAPTUSP2RECQLHSD17B10POLB
SCHEMBL3015477 0.90 MAPT (0.47) MAPTUSP2RECQLHSD17B10POLB
SCHEMBL3006060 0.90 MAPT (0.49) MAPTUSP2RECQLHSD17B10POLB
SCHEMBL3007925 0.89 MEN1 (0.46) MAPTUSP2RECQLHSD17B10POLB
SCHEMBL3016535 0.89 LMNA (0.44) MAPTUSP2RECQLHSD17B10POLB
SCHEMBL3020101 0.89 ALDH1A1 (0.43) MAPTUSP2RECQLHSD17B10POLB
SCHEMBL3008922 0.89 ALDH1A1 (0.50) MAPTUSP2RECQLPOLBALDH1A1
SCHEMBL3012688 0.88 USP2 (0.51) MAPTUSP2RECQLHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.